About us

Company Overview

Resalis Therapeutics is a biopharma company focused on the development of oligonucleotide anti-sense therapies to treat metabolic disorders, including MAFLD/NAFLD/NASH, obesity, and cancer. The company leverages on the scientific research of a team of internationally renowned scientists.

Pressured by unmet clinical needs affecting tenths of millions of patients in the world, Resalis Therapeutics is advancing its pipeline of first-in-class anti-miRNA compounds toward clinical validation, supported by robust preclinical evidence generated at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston – US) and Aalborg University (Copenhagen, Denmark).

Our Team

Eva Castagnetti – CEO

Eva studied chemistry and obtained a PhD from the UNIL/EPFL Lausanne. After a post-doc in biochemistry at the Massachusetts Institute of Technology (MIT) and at the ETH (Zurich), she started working at Lonza as responsible for process development, manufacturing and scale-up of new medicaments (peptides and oligonucleotides) in preclinical and clinical phases, before joining two biotech start-ups as responsible for project management, director of product development and member of the management team, gaining an important overview of the entire drug development process, as well as experience in the interaction with stakeholders such as regulatory authorities (FDA, EMEA), external CROs/CMOs and suppliers, VC investors, Pharma partners. Eva also worked for big Pharma (Novartis) where she led and coordinated international cross-functional teams developing new drugs across indications and product modalities (cell and gene-CRISPR, RNA, peptides, biologics, small molecules). Eva’s interest and passion for start-ups, innovation and investing pushed her to be an active private investor, mentor and board member in several deep-tech companies.

Riccardo Panella – Scientific Founder and BoD Member

Riccardo Panella, PhD, Assistant Professor in Cancer Biology and Genetics at the Center for Genomic Medicine at Desert Research Institute. He obtained his PhD in Molecular Oncology in 2013 at the University of Perugia in Italy after which he was awarded a post-doctoral fellowship form the Marie Curie Foundation in 2014. He worked for six years at Beth Israel Deaconess Medical Center Cancer Institute / Harvard Medical School Cancer Center. Dr. Panella has focused his entire career on translational medicine, with the main goal of developing new treatment options and new therapeutic approaches to disease. His expertise lies in the application of non-coding RNA as both a therapeutic target and as a cutting-edge technology for developing new therapeutic paradigms. In the laboratory, his team is currently investigating the role of non-coding RNAs in metabolic homeostasis and how it affects human metabolism. Specifically, they are striving to understand non-coding RNA’s metabolic functions in cancer and other metabolically relevant diseases to disentangle the mechanistic relationship between microRNAs, metabolism, and cancer progression, particularly in advanced and metastatic tumors. These studies include investigations of the roles on non-coding RNA in multiple types of cancer, including, but not limited to: breast cancer, leukemia, lung, and liver cancer.

Pietro Puglisi – BoD Member & Chairman

Pietro is a biomedical engineer with over a decade of experience in life sciences investments and innovation. He is a founding partner at Claris Ventures, investment firm based in Turin (Italy), with focus on early-stage biotech ventures. He started his career at LifeSciences Consultants in 2010 and later joined Innogest VC firm’s healthcare practice. Prior to launching Claris Ventures, he was involved in financing rounds of several Italy-based biopharma startup companies, acting as an independent director at Kither Biotech (PI3Kγ-inhibitors for cystic fibrosis treatment) and Restorative Neurotechnologies (digital therapies for neurological rehab). Pietro received an M.Sc. in Biomedical Engineering from Politecnico di Torino (Italy) and an MBA from Collége des Ingenièurs (France/Italy).

Antonio Leone – BoD Member

Electronics engineer with over 40 years of experience in the electromedical equipment industry, Antonio was President and Worldwide CEO of Kontron Instruments Roche group. In 1993 he moved to Olympus group, where he assumed the position of CEO of Olympus Medical System Europe Hamburg, with a turnover of 700 million euros and 2300 employees. Antonio was BELLCO Chairman of the Charme fund managed by Montezemolo & Partners SGR and currently holds, among others, the position of Board Member of Cellply S.r.l. Since 2014 he holds the position of President in IAG – Italian Angels for Growth.

Mike Hodges – BoD Member and Scientific Advisor

Michael is a highly experienced successful pharmaceutical industry veteran with experience in big PHARMA and Biotech. He has experience with eight drug development programs that have led to global regulatory approvals.  He was part of teams that raised $157MM dollars in Series B and C rounds of financing, one F-1 submission for IPO, one reverse merger and two successful M&As.  He has deep disease-specific and RNA therapeutics technical expertise. He is currently supporting a number of Biotechnology companies in the role of drug development consultant, scientific advisor and/or board director. He is a member of the science advisory boards of Arcturus Therapeutics, Exicure Therapeutics and eFFECTOR Therapeutics and a scientific advisor for Adjuvant Capital.  Michael was previously the CMO of Amplyx Pharmaceuticals, developing drug treatments for life-threatening viral and fungal infections in immunocompromised patients. The company was acquired by Pfizer, Inc. Prior to Amplyx he was the CMO for Santaris A/S, developing drug treatments for chronic viral diseases, cancer, metabolic/lipid and eye diseases. The company was acquired by Hoffman-La Roche, AG.  Michael started his career in pharmaceutical medicines with Pfizer Global Research and Development where he worked on multiple infectious diseases and oncology development programs. Under his leadership two antifungal drugs where approved, VFEND® (voriconazole) and ERAXIS™ (anidulafungin).  Michael was a Non-Executive Director of F2G Ltd., an infectious disease biotechnology company from 2010-2014. He earned his M.D. (MBBS) and BSc. in Pharmacology, from the University of London, UK.

Sakari Kauppinen – Scientific Founder and Scientific Advisor

Sakari Kauppinen serves as Professor at the Department of Clinical Medicine, Aalborg University and Director of the Center for RNA Medicine. Dr. Kauppinen earned his M.Sc. in Genetics from the University of Helsinki and his Ph.D. in Molecular Biology from the University of Copenhagen followed by postdoctoral training at the GeneExpress Research Satellite, Novo Nordisk, Denmark. His research focuses on exploring the roles of microRNAs, long noncoding RNAs and circular RNAs in human health and disease and discovering RNA-targeted therapeutics for unmet medical needs. Before joining Aalborg University, Dr. Kauppinen was Senior Director of MicroRNA Research and Drug Discovery at Santaris Pharma, and Head of the microRNA Research Unit at the Department of Cellular and Molecular Medicine, University of Copenhagen, where he was responsible for multiple microRNA research and drug discovery programs in cancer, cardiometabolic and infectious diseases, including the discovery of the world’s first microRNA‐targeted medicine, miravirsen. He was also a member of the miravirsen clinical development team that has successfully advanced this microRNA drug to clinical phase 2 trials for the treatment of chronic hepatitis C virus infection with proven efficacy against HCV and a good safety profile.

Luciano Adorini – Scientific Advisor

Luciano has served as Intercept’s Chief Scientific Officer from 2008 until recently when he has named Head of External Scientific Research. He has over 30 years of pharmaceutical industry experience. He was a co-founder and Chief Scientific Officer at BioXell S.p.A., where he was responsible for advancing a pipeline of products based on vitamin D receptor agonists in multiple disease indications. During his tenure, BioXell raised significant capital from international venture capital firms, and was listed at the Swiss stock exchange. Earlier in his career, he served as associate director of Roche Milano Ricerche, and was research director of a unit at the Preclinical Research Center, Sandoz Pharma, Ltd., in Basel, Switzerland. He has authored over 300 journal articles and other scientific publications, becoming a highly cited researcher in immunology, with a focus on immune suppressive and immunoregulatory mechanisms in the treatment of inflammatory and autoimmune diseases. He is a board member of a number of peer-reviewed publications and has served as president of the Italian Society of Immunology, Clinical Immunology and Allergology.